NovAccess Global Appoints Dwain Irvin, Ph.D., MPH as New Chief Executive Officer

Rhea-AI Summary

NovAccess Global (OTC PINK:XSNX) has appointed Dr. Dwain Irvin as CEO, signaling a commitment to advancing biomedical initiatives. Dr. Irvin, a seasoned cancer researcher with a PhD from UCLA, previously led the Biotechnology division at Innovest Global Inc. His extensive background includes research on neural stem cells and immunotherapy for brain tumors. This leadership change is expected to enhance the company's strategic direction and drive its commercial objectives.

Positive

• Appointment of Dr. Dwain Irvin as CEO, bringing valuable experience in cancer research and biotechnology.
• Dr. Irvin's leadership in developing immunotherapies for brain tumors may position NovAccess favorably in the biomedical field.

Negative

• Potential concerns regarding continuity in leadership and experience gaps from previous management.

Leadership by world-renown cancer researcher signals commitment to driving current and forthcoming biomedical opportunities

CLEVELAND, OH / ACCESSWIRE / October 15, 2020 / NovAccess Global, Inc. (OTC PINK:XSNX), announced today the addition of published researcher, and patent author Dr. Dwain Irvin as CEO. Dr. Irvin steps into the role after heading the Biotechnology division for Innovest Global Inc.

Dr. Irvin received his PhD from UCLA School of Medicine, MPH, from UCLA School of Public Health, and trained at The Wallenberg Neuroscience Center at Lund University in Lund, Sweden. He was also a Professor, Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery.

Dr. Irvin received his PhD in Pharmacology and Developmental Neuroscience with an emphasis on neural stem cell fate and differentiation. His research focused on neural development and Notch Signaling in mammalian neural stem cells. He also worked as an NIH/NINDS Post-Doctoral Fellow in

Dr. Anders Bjorklund laboratory in Lund, Sweden. There, his focus was on research projects that investigated the potential role of cell replacement therapy for patients with Parkinson's disease. They developed several protocols for the efficient generation of dopaminergic neurons from forebrain and ventral midbrain stem and progenitor cells. Dr. Irvin also worked as a Research Scientist, Assistant Professor, and Faculty member at Cedars-Sinai Medical Center, Department of Neurosurgery. He led research investigations in the role of adaptive immunity in Parkinson's disease. He also developed two patents in the area of immunotherapy for brain tumor patients, specifically Glioblastoma Multiforme (GBM). His research team focused on molecular mechanisms that impart therapeutic resistance in cancer cells, including cancer stem cells. They utilized these data to develop novel immunotherapies for brain tumor patients. Dr. Irvin's leadership experience in academia, hospital systems, private and public biotech companies will add extraordinary value to NovAccess Global.

Look for much more information to come soon as the company completes its immediate commercial objectives.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown uncertainties and other factors which are, in some cases, beyond the Company's control, which could, and likely will materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. Such risks, uncertainties, and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Investor Contact:
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
IVST@mzgroup.us
www.mzgroup.us

Brokers and Analysts:
Chesapeake Group
+1-410-825-3930
info@chesapeakegp.com

SOURCE: NovAccess Global Inc.

View source version on accesswire.com:
https://www.accesswire.com/610668/NovAccess-Global-Appoints-Dwain-Irvin-PhD-MPH-as-New-Chief-Executive-Officer

FAQ

Who has been appointed as the new CEO of NovAccess Global?

Dr. Dwain Irvin has been appointed as the new CEO of NovAccess Global.

What are Dr. Dwain Irvin's qualifications?

Dr. Irvin holds a PhD from UCLA and has extensive experience in cancer research and biotechnology.

What impact might Dr. Irvin's appointment have on NovAccess Global?

His expertise in cancer research may enhance the company's strategic direction and research initiatives.

What company is represented by the stock symbol XSNX?

XSNX represents NovAccess Global, Inc.